Aimovig (Erenumab) belongs to the class of medications called Calcitonin gene-related peptide receptor antagonists. Aimovig (Erenumab) is used to prevent migraine in adults who experience 4 or more migraine days each month.
Available form
Injectable, Injectable
Dosage
Manufacturer
Novartis Pharmaceuticals
We won't bore you with the details, but Health Canada requires you to sign in.
By proceeding you agree to our Terms of Use & Privacy Policy
The recommended dose of Aimovig (Erenumab) is 70 mg injected subcutaneously (under the skin) once a month. Depending on how you respond to Aimovig (Erenumab), your doctor may prescribe a maximum dose of 140 mg injected once a month. Each prefilled syringe or autoinjector of Aimovig (Erenumab) is single use only and should be safely discarded after the dose has been injected.
Aimovig (Erenumab) is administered by subcutaneous injection in the thigh, buttocks, or abdomen. It is important to rotate the site of injection. Allow the medication to reach room temperature by removing it from the refrigerator at least 30 minutes before injecting it. Do not heat the syringe or autoinjector to warm the medication. Do not shake Aimovig (Erenumab) before using it. The solution for injection should be clear-to-slightly-opalescent and colourless-to-slightly-yellow. If it is cloudy or you can see lumps, flakes, or coloured particles in the solution, do not use it.
If you are using Aimovig (Erenumab) at home, your doctor will ensure that you understand exactly how to use it. Make sure you ask any and all questions necessary to ensure that you use it exactly as prescribed. Please refer to the appropriate package insert for details on how to mix the medicine and for proper injection procedures. It is important to visit your doctor regularly during therapy to ensure that the medication is working safely and effectively.
Many things can affect the dose of medication that a person needs, such as body weight, other medical conditions, and other medications. If your doctor has recommended a dose different from the ones listed here, do not change the way that you are taking the medication without consulting your doctor.
It is important to take Aimovig (Erenumab) exactly as prescribed by your doctor.
If you miss a dose, take it as soon as possible. The following dose should be given one month after the missed dose has been used. Do not take a double dose to make up for a missed one. If you are not sure what to do after missing a dose, contact your doctor or pharmacist for advice.
Store Aimovig (Erenumab) in the refrigerator, protect it from light and moisture, and keep it out of the reach of children. Do not allow Aimovig (Erenumab) to freeze. Once Aimovig (Erenumab) has been removed from the refrigerator, it may be kept at room temperature (up to 25°C) for up to 14 days. Do not put Aimovig (Erenumab) that has reached room temperature back in the refrigerator.
Do not dispose of medications in wastewater (e.g. down the sink or in the toilet) or in household garbage. Ask your pharmacist how to dispose of medications that are no longer needed or have expired.
Many medications can cause side effects. A side effect is an unwanted response to a medication when it is taken in normal doses. Side effects can be mild or severe, temporary or permanent.
The side effects listed below are not experienced by everyone who takes Aimovig (Erenumab). If you are concerned about side effects, discuss the risks and benefits of Aimovig (Erenumab) with your doctor.
The following side effects have been reported by at least 1% of people taking Aimovig (Erenumab). Many of these side effects can be managed, and some may go away on their own over time.
Contact your doctor if you experience these side effects and they are severe or bothersome. Your pharmacist may be able to advise you on managing side effects.
Stop taking the medication and seek immediate medical attention if any of the following occur:
Some people may experience side effects other than those listed. Check with your doctor if you notice any symptom that worries you while you are taking Aimovig (Erenumab).
70 mg/mL
Each 1 mL of clear-to-opalescent and colourless-to-light-yellow, preservative-free, sterile solution, contains 70 mg Aimovig (Erenumab). Nonmedicinal ingredients: glacial acetic acid, polysorbate 80, sucrose, water for injection, and sodium hydroxide to pH of 5.2.
The needle cover of the glass prefilled syringe and the autoinjector contain natural rubber latex.
140 mg/mL
Each 1 mL of clear-to-opalescent and colourless-to-light-yellow, preservative-free, sterile solution, contains 140 mg of Aimovig (Erenumab). Nonmedicinal ingredients: glacial acetic acid, polysorbate 80, sucrose, water for injection, and sodium hydroxide to pH of 5.2.
The needle cover of the autoinjector contains natural rubber latex.
Do not take Aimovig (Erenumab) if you are allergic to Aimovig (Erenumab) or any ingredients of the medication.
Tell your doctor or prescriber about all prescription, over-the-counter (non-prescription), and herbal medications you are taking. Also tell them about any supplements you take. Since caffeine, alcohol, the Nicotine from cigarettes, or street drugs can affect the action of many medications, you should let your prescriber know if you use them. Depending on your specific circumstances, your doctor may want you to:
An interaction between two medications does not always mean that you must stop taking one of them. Speak to your doctor about how any drug interactions are being managed or should be managed.
Before you begin using a medication, be sure to inform your doctor of any medical conditions or Allergies you may have, any medications you are taking, whether you are pregnant or breast-feeding, and any other significant facts about your health. These factors may affect how you should use Aimovig (Erenumab).
Allergic reactions: In rare cases, some people may develop an allergic reaction to Aimovig (Erenumab). Signs of an allergic reaction include a severe rash, Hives, swollen face or throat, or difficulty breathing. If these occur, contact your doctor immediately.
Pregnancy: Aimovig (Erenumab) should not be used during pregnancy unless the benefits outweigh the risks. If you become pregnant while taking Aimovig (Erenumab), contact your doctor immediately.
Breast-feeding: It is not known if Aimovig (Erenumab) passes into breast milk. If you are a breast-feeding mother and are taking Aimovig (Erenumab), it may affect your baby. Talk to your doctor about whether you should continue breast-feeding.
Children: The safety and effectiveness of using Aimovig (Erenumab) have not been established for children.
Seniors: The safety and effectiveness of using Aimovig (Erenumab) have not been established for people over the age of 65.
It’s like having us in your pocket, putting you first in every interaction.
Your medication is delivered to you at no added cost.
Call, text, email—whatever works for you. We’re humans, ready to help.
Discreet with real-time updates. Go about your day, your meds are on the way.
Your region
,
Pocketpills is licensed by
Accreditation No
#
Pharmacy Manager
2025 Pocketpills
Pocketpills is not a pharmacy
or a drug manufacturer
